Demand for Long Acting Birth Control Pills
The contraceptives market has a strong pipeline supporting growth in the market and attracting many pharmaceutical and biotechnological companies. Major pharmaceutical companies such as Teva, Watson, Bayer and Merck have active contraceptive pipelines. One of the major activities in the market at present is the development of generic versions of off patent drugs. The entry of these generic versions will boost the oral contraceptive market and thereby bring about further rises in the hormonal contraceptives market in the coming years. The rapid entry of new players is set to intensify competition in this market. Also, the presence of a highly active pipeline is an indicator of strong market competition in the future.
‘In 2009, the global contraceptives market was estimated at $11.2 billion, and achieved a CAGR of 7% between 2001 and 2009. The market is forecast to record revenues of $14.5 billion by 2016, growing at a CAGR of 4% between 2009 and 2016.’
GBI Research’s report ‘Contraceptive Market to 2016 -Demand for Long Acting Birth Control Pills Encourages Growth in Hormonal Contraceptives Market’ provides a detailed insight in to the contraceptive market to 2016. In-depth analyses on the global contraceptive treatment usage patterns and the contraceptive markets in key geographies, namely the US, top five EU countries and Japan are covered in the report. Details about contraceptive R&D pipelines and potential future blockbuster products are also provided. The report also explores the competitive landscape, with a competitive analysis of the top companies in the market and a key trend analysis of mergers and acquisitions and licensing agreements in the contraceptives market.